Multicenter, single-arm, observational study of mean duration of trastuzumab treatment for early and metastatic breast cancer in Romanian population (HERODOT Study)
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2016
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HERODOT
- Sponsors Roche
- 04 May 2016 Status changed from active, no longer recruiting to discontinued.
- 31 Jul 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 31 Jul 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.